Product Information
CAPECITABINE 500 MG TABLET is a generic product labeled by Cipla USA Inc., priced at $0.4556 per EA under NDC 69097094808. Its NADAC has been published 361 times since Nov 21, 2018.
FDA first approved this application on Jul 2, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
500 mg/1
Manufacturer
Cipla USA Inc.NDC
69097094808
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CAPECITABINEApproval Type
Generic (ANDA)
FDA Application
ANDA209365FDA Approved
7/2/2018
TE Code
AB
On Market Since
7/1/2023
Pharmacological Classes
Price Statistics
The NADAC for CAPECITABINE 500 MG TABLET has been published 361 times since Nov 21, 2018, and over the history we have for it it has declined 89.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4556 per EA |
|---|---|
| All-time high | $4.2997 (Jan 16, 2019) |
| All-time low | $0.4342 (Nov 20, 2024) |
| 52-week high | $0.5336 |
| 52-week low | $0.4556 |
| Median price | $0.5863 |
| Average price | $1.2841 |
| Largest weekly change | -67.4% (Dec 23, 2020) |
| Weeks tracked | 361 |
| Tracking since | Nov 21, 2018 |
Generic Alternatives
The matcher finds 11 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Capecitabine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nucleoside Metabolic Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CAPECITABINE 500 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CAPECITABINE 500 MG TABLET, manufactured by Cipla USA Inc., is $0.4556 per EA (NDC 69097094808), effective Sep 30, 2026.
How has the price of CAPECITABINE 500 MG TABLET changed over time?
Over the history we have for it, the NADAC for CAPECITABINE 500 MG TABLET has declined 89.4%. It has been tracked across 361 weekly CMS publications since Nov 21, 2018.
What are the highest and lowest recorded NADAC prices for CAPECITABINE 500 MG TABLET?
Since Nov 21, 2018, the NADAC for CAPECITABINE 500 MG TABLET has ranged from a low of $0.4342 (Nov 20, 2024) to a high of $4.2997 (Jan 16, 2019), with a median of $0.5863 per EA.
Are there cheaper alternatives to CAPECITABINE 500 MG TABLET?
11 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CAPECITABINE 500 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CAPECITABINE 500 MG TABLET?
CAPECITABINE 500 MG TABLET (NDC 69097094808) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.